10-Q quarterly report · filed Nov 4, 2026

GERON CORP (GERN) Q3 2026 10-Q Quarterly Report

Short answer

GERON CORP (GERN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $60M (up 27.4% year over year) with net income of $1M.

Q3 2026 key financials · XBRL

Revenue
$60M
+27.4% YoY · +4.7% QoQ
Net income
$1M
+107.3% YoY · +108.1% QoQ
Operating margin
9.6%
EPS (diluted)
$0.00
+100.0% YoY · +100.0% QoQ

Source: XBRL data from the GERON CORP (GERN) Q3 2026 10-Q on SEC EDGAR. USD.

GERON CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $60.2M, up $13.0M YoY from $47.2M, driven by RYTELO product revenue
  • Net income $1.4M vs $18.4M loss YoY, operating margin 9.6% vs (29.4)%
  • RYTELO product revenue $60.1M, up $12.9M YoY, the only disclosed product line
  • Cash, equivalents, restricted cash and securities $339.4M vs $401.1M at December 31, 2025
  • Outlook: Germany availability expected by end-2026, Q4 gross-to-net adjustments expected in low to mid-twenties percentage range

Risk Factors

  • Newly triggered clinical-development risk: IMpactMF Phase 3 discontinued in October 2026 after an independent DMC found overall survival endpoint unlikely
  • Most material commercial update: RYTELO revenue $169.4 million vs $135.6 million for nine months ended September 30, 2026 and 2025, respectively
  • Regulatory risk: FDA and EU approvals require long-term safety studies and alternative-dosing trials, with potential penalties or withdrawal for noncompliance
  • Near-term market risk: revised U.S. strategy targets high-volume earlier-line accounts and non-personal promotion after sales growth remained limited
  • Financial risk: $125.0 million Pharmakon term loan secured by substantially all assets, including intellectual property, with Tranche B and C no longer available

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other GERON CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.